Replies to post #254214 on Biotech Values

[Mufaso]

jbog- I hope you are correct. I still hold the opinion I shared from November in #msg-175330867 right after obesity week which was:

FWIW- A buyout may happen soon (within 1 year) or maybe Viking goes it alone (with a CDMO partner). I myself am playing the long game on VKTX.

Viking has become a very divisive stock. I'm amazed that short position is at an all time high . They have had nothing but good news on their end and competing late stage drugs have disappointed recently. I'm also amazed it only has a market cap of 4.3B given

• VK2735 has BIC potential in a ~100b market with a drug that can be either subq or oral
  
• They have ~930M in cash
  
• They have 2 other significant assets in VK2809 for NASH and VK0214 for X-ALD.

The market cap is so low considering the assets, I almost think a group of VC's/Investment firms might take a run at Viking with an unsolicited offer sub 10B. No, I don't think it's likely but given what they and others are willing to shell out for unproven pre clinical assets in this space, it might become a real possibility if VKTX goes lower.

While I still think a buyout is the most probable, I do think the option for VKTX to go it alone is real (and will post on this separately.) What I don't think is that the shorts are right.

FWIW- If I'm wrong, I may have to eat my hat simply because I may not have anything else to eat. :-)